Your session is about to expire
← Back to Search
Cancer Vaccine
HPV Vaccination Strategies for Cervical Cancer Prevention (IVaccinate Trial)
N/A
Waitlist Available
Led By Electra D Paskett
Research Sponsored by Ohio State University Comprehensive Cancer Center
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial Must have
Timeline
Screening 3 weeks
Treatment Varies
Follow Up up to 60 months
Awards & highlights
No Placebo-Only Group
Summary
This trial is testing a new way to get people to get the HPV vaccine in four states in America. The HPV vaccine can help prevent cervical cancer.
Who is the study for?
This trial is for healthcare providers and office staff in certain Appalachian states who care for patients aged 11-26, provide immunizations, and are involved in the vaccine process. Participants must be able to speak, read, and write English.
What is being tested?
The study tests if using educational materials, promotional efforts, and electronic health record reminders can increase HPV vaccination rates among children and young adults within four Appalachian state health systems.
What are the potential side effects?
Since this trial focuses on improving vaccination rates through interventions like education rather than testing a new drug or vaccine itself, it does not directly involve medical side effects.
Timeline
Screening ~ 3 weeks3 visits
Treatment ~ Varies
Follow Up ~ up to 60 months
Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~up to 60 months
Treatment Details
Study Objectives
Study objectives can provide a clearer picture of what you can expect from a treatment.Primary study objectives
Change in attitudes of providers
Change in knowledge of providers
Change in rate of HPV vaccination initiation among those 13-26
+3 moreAwards & Highlights
No Placebo-Only Group
All patients enrolled in this study will receive some form of active treatment.
Trial Design
2Treatment groups
Experimental Treatment
Group I: ARM II (DELAYED INTERVENTION)(education, reminder, usual care)Experimental Treatment4 Interventions
Health systems, providers, and patients receive usual care for 12 months, then receive multi-level intervention as in Arm I.
Group II: ARM I (EARLY INTERVENTION) (educational material, reminders)Experimental Treatment4 Interventions
Health systems receive educational materials consisting of posters, brochures and handouts. Providers complete survey about HPV knowledge, participate in educational session over 1 hour and receive educational handouts on the HPV vaccine. Patients receive educational materials about HPV vaccine and reminder letters for HPV vaccination
Find a Location
Who is running the clinical trial?
National Cancer Institute (NCI)NIH
13,958 Previous Clinical Trials
41,111,080 Total Patients Enrolled
Ohio State University Comprehensive Cancer CenterLead Sponsor
342 Previous Clinical Trials
291,707 Total Patients Enrolled
Electra D PaskettPrincipal InvestigatorOhio State University Comprehensive Cancer Center
Media Library
Eligibility Criteria:
This trial includes the following eligibility criteria:- The trial does not include healthcare providers, such as doctors, nurses, and office staff.People who work with the vaccine at the clinic.You are able to communicate in English through speaking, reading, and writing.You live in one of the areas that are included in this program.You must be able to understand and communicate in English as there are not many Spanish speakers in the study area.I provide care to patients aged 11-26.I am up to date with my vaccinations.You receive medical care from one of the participating healthcare organizations.I'm sorry, it seems like there's not enough information to rewrite this criterion. Can you please provide more context or details?
Research Study Groups:
This trial has the following groups:- Group 1: ARM I (EARLY INTERVENTION) (educational material, reminders)
- Group 2: ARM II (DELAYED INTERVENTION)(education, reminder, usual care)
Awards:
This trial has 1 awards, including:- No Placebo-Only Group - All patients enrolled in this study will receive some form of active treatment.
Timeline:
This trial has the following timeline:- Screening: It may take up to 3 Weeks to process to see if you qualify in this trial.
- Treatment: The duration you will receive the treatment varies.
- Follow Ups: You may be asked to continue sharing information regarding the trial for 6 Months after you stop receiving the treatment.